PAS
CUE icon

Point72 Asia (Singapore)’s Cue Biopharma CUE Stock Holding History

Point72 Asia (Singapore)’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-925
Closed -$30.3K – 938
2024
Q4 		$30.3K Buy
925
+122
+15% +$4.58K 0.01% 599
2024
Q3 		$18.2K Sell
803
-965
-55% -$20.9K ﹤0.01% 827
2024
Q2 		$65.8K Buy
+1,768
New +$87.4K 0.01% 580

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Point72 Asia (Singapore)'s CUE Position: Q1 2025 in Review

Point72 Asia (Singapore) sold out of Cue Biopharma (CUE) in Q1 2025, closing a stake of 925 shares — an estimated $30.3K sold.

Point72 Asia (Singapore) first reported a position in CUE in Q2 2024 and held it in 3 quarters. The position peaked at $65.8K in Q2 2024. 49 funds tracked by Wall St. Rank hold CUE as of Q1 2025.

  • Point72 Asia (Singapore) reported no remaining Cue Biopharma position as of Q1 2025 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 925 Cue Biopharma shares in Q1 2025, an estimated $30.3K.
  • Point72 Asia (Singapore) first reported a position in Cue Biopharma in Q2 2024 and held it in 3 quarters.
  • Point72 Asia (Singapore)'s Cue Biopharma position peaked at $65.8K in Q2 2024.
  • 49 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q1 2025, filed 15 May 2025.